MedPath

GlaxoSmithKline

GlaxoSmithKline logo
🇬🇧United Kingdom
Ownership
Public
Established
1929-01-01
Employees
70.2K
Market Cap
$90B
Website
http://www.gsk.com
Introduction

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine

Phase 4
Completed
Conditions
Rhinitis, Allergic, Seasonal
First Posted Date
2007-02-15
Last Posted Date
2018-03-07
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
1000
Registration Number
NCT00435461
Locations
🇺🇸

GSK Investigational Site, San Antonio, Texas, United States

Study Of Safety, Blood Levels, And Brain Receptor Occupancy Of GSK163090 Using PET Imaging In Healthy Males

Phase 1
Completed
Conditions
Healthy Subjects
Depressive Disorder and Anxiety Disorders
Interventions
First Posted Date
2007-02-15
Last Posted Date
2012-06-04
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
13
Registration Number
NCT00435695
Locations
🇨🇦

GSK Investigational Site, Toronto, Ontario, Canada

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Phase 1
Completed
Conditions
Infections, Cytomegalovirus
Interventions
Biological: GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A
First Posted Date
2007-02-15
Last Posted Date
2017-05-30
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
40
Registration Number
NCT00435396
Locations
🇧🇪

GSK Investigational Site, Wilrijk, Belgium

Evaluation of Efficacy and Safety of Omacor, Co-Administered With Atorvastatin, in Subjects With Hypertriglyceridemia

First Posted Date
2007-02-14
Last Posted Date
2017-02-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
245
Registration Number
NCT00435045

Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)

Phase 2
Completed
Conditions
Parkinson Disease
Interventions
First Posted Date
2007-02-13
Last Posted Date
2018-09-27
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
62
Registration Number
NCT00434304
Locations
🇯🇵

GSK Investigational Site, Tokyo, Japan

Safety and Immunogenicity of the Zoster Vaccine GSK1437173A in Elderly Subjects

Phase 2
Completed
Conditions
Herpes Zoster
Interventions
Biological: Herpes Zoster vaccine GSK1437173A Modified
Biological: Herpes Zoster vaccine GSK1437173A Low Dose
Biological: Herpes Zoster vaccine GSK1437173A High Dose
Biological: Herpes Zoster vaccine GSK1437173A Medium Dose
Biological: Placebo
First Posted Date
2007-02-13
Last Posted Date
2019-03-15
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
715
Registration Number
NCT00434577
Locations
🇸🇪

GSK Investigational Site, Uppsala, Sweden

Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

Phase 2
Completed
Conditions
AIDS
HIV Infections
Interventions
Biological: HIV vaccine 732461
First Posted Date
2007-02-13
Last Posted Date
2019-10-01
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
180
Registration Number
NCT00434512
Locations
🇧🇪

GSK Investigational Site, Gent, Belgium

A Study Of BRL49653C For The Treatment Of Type 2 Diabetes (Combination Therapy With Sulfonyl Urea) -With Placebo Study

Phase 3
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2007-02-08
Last Posted Date
2022-12-12
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
149
Registration Number
NCT00432679
Locations

GSK Investigational Site

A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.

Phase 2
Completed
Conditions
Rotavirus Vaccines
Infections, Rotavirus
Interventions
Biological: Placebo
Biological: Rotarix™
First Posted Date
2007-02-07
Last Posted Date
2020-01-02
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
375
Registration Number
NCT00432380
Locations
🇵🇭

GSK Investigational Site, Muntinlupa, Philippines

A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy

Phase 3
Completed
Conditions
Nausea and Vomiting, Chemotherapy-Induced
First Posted Date
2007-02-05
Last Posted Date
2017-08-22
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
810
Registration Number
NCT00431236
Locations
🇺🇦

GSK Investigational Site, Uzhgorod, Ukraine

© Copyright 2025. All Rights Reserved by MedPath